NASDAQ inches higher as VIX plummets

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Markets continue their float higher as selling pressure seems to be waning. Volatility is finally starting to make a meaningful contraction, with the VIX down over 10% on the day.

VIX Hourly Chart

If the VIX starts closing below $50 on a dail basis, we could see the VIX start to come in quickly. However, that won’t necessarily mean the market runs that much further.

We’re probably seeing the equity run wane but not roll over. This is leading to more people lightening up on their protection the longer this goes on.

Additionally, we still haven’t seen the VVIX move off yet, but it also hasn’t held up as well.

VVIX Hourly Chart

The key level here is $150. Daily closes below this spot should bring the VVIX down do around $120 (which is still pretty darn high.

Bonds are really interesting. They’re holding in this range that keeps narrowing down. Typically, this means they’re about to break out with an expansive move. That could be something we see sooner rather than later.

TLT Daily Chart

Similarly, we’re seeing the dollar follow a pattern where it started in a wide range and then moved back into a more narrow path.

UUP Daily Chart